MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1

K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, D. Rukina, J. Anzures Cabrera, L. Essioux, M. Abt, B. van Lier, A. Thomann, H. Svoboda, W. Zago, R. Postuma, G. Pagano, M. Lindemann (Basel, Switzerland)

Meeting: MDS Virtual Congress 2021

Abstract Number: 447

Keywords: Alpha-synuclein, Bradykinesia, Parkinson’s

Category: Parkinson’s Disease: Clinical Trials

Objective: To determine whether digital biomarker sensor data detect slowing in progression of core motor features of Parkinson’s disease (PD) in individuals with early PD treated with prasinezumab.

Background: Prasinezumab was designed to target aggregated alpha-synuclein and slow disease progression in PD. A primary challenge in clinical development is the variability in disease progression measurements, presumably reflecting the fluctuating nature of PD signs and infrequent site visit assessments with different and changing clinical raters. Daily measurement of PD core motor features with digital health technology tools may represent a potential solution to this challenge, enabling frequent and objective measurements.

Method: A total of 316 participants of the Phase II PASADENA Part 1 study (NCT03100149) were randomized 1:1:1 to placebo, prasinezumab 1500 mg  and 4500 mg  dose groups, whereby pooled dose groups were analyzed here. All received a smartphone/watch, performed daily active motor tests, and carried/wore devices throughout the day. A total of 17 pre-specified sensor features extracted from active test and passive monitoring data were aggregated within participants over fortnights. Linear data were analysed with linear mixed effect models (LMEs) with random slopes fitting each feature’s change from baseline. Mixed Models for Repeated Measurements  (MMRM) were used for nonlinear data. Effects of interest were defined as p<0.2, and a 15% false discovery rate was applied.

Results: Median adherence was 93.1%, with 75% of patients with mean adherence >75.9%. A total of 5 out of 17 sensor features progressed less in the prasinezumab vs. placebo group: LMEs: speeded tapping variability (each side), U-turn test max. turn speed; MMRMs: maximum pronation/supination speed (most affected side), power of gestures in daily life. Spiral drawing celerity (i.e. accuracy/time), least affected side, showed an effect favoring placebo (LME). Two analyses survived FDR-correction, both favoring prasinezumab: speeded tapping least affected side and gesture power in daily life (see Figure).

Conclusion: The Roche PD Mobile Application v2 demonstrated decreased one-year progression of bradykinesia in prasinezumab vs. placebo treated individuals with early PD, consistent with a disease-modifying effect of prasinezumab.

TaylorEtc Figure

To cite this abstract in AMA style:

K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, D. Rukina, J. Anzures Cabrera, L. Essioux, M. Abt, B. van Lier, A. Thomann, H. Svoboda, W. Zago, R. Postuma, G. Pagano, M. Lindemann. Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1 [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/prasinezumab-reduced-progression-of-parkinsons-disease-motor-features-measured-by-roche-pd-mobile-application-v2-sensor-features-pasadena-phase-ii-part-1/. Accessed June 24, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/prasinezumab-reduced-progression-of-parkinsons-disease-motor-features-measured-by-roche-pd-mobile-application-v2-sensor-features-pasadena-phase-ii-part-1/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Welcome to the MDS Abstracts Site
    • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • Life expectancy with and without Parkinson’s disease in the general population
    • The hardest symptoms that bother patients with Parkinson's disease
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley